102791-92-4

Basic information

• Product Name: 1-(3-Methyl-4-nitrophenyl)-1H-imidazole
• Synonyms: 1-(3-Methyl-4-nitrophenyl)-1H-imidazole
• CAS NO: 102791-92-4
• Molecular Formula: C₁₀H₉N₃O₂
• Molecular Weight: 203.19736
• Mol File: 102791-92-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 112-115 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 385.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Methyl-4-nitrophenyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Methyl-4-nitrophenyl)-1H-imidazole(102791-92-4)
• EPA Substance Registry System: 1-(3-Methyl-4-nitrophenyl)-1H-imidazole(102791-92-4)

Safety Data

• Hazardous Substances Data: 102791-92-4(Hazardous Substances Data)

Usage

Structure

A derivative of imidazole with a five-membered aromatic ring containing two non-adjacent nitrogen atoms.

Substituents

Contains a nitro group (-NO2) and a methyl group (-CH3) attached to the phenyl ring.

Functional groups

Imidazole, phenyl, nitro, and methyl.

Application

Used in organic synthesis and medicinal chemistry for the development of pharmaceutical drugs and biologically active molecules.

Research and industrial applications

Serves as an intermediate in the production of other compounds and as a reagent in chemical reactions.

Suitability

Its structure and chemical properties make it suitable for various research and industrial applications.

Upstream product

• 288-32-4 1H-imidazole 
• 446-33-3 5-Fluoro-2-nitrotoluene 
• 73746-45-9 4-iodo-2-methyl-1H-imidazole 

Downstream Products

• 118111-96-9 4-imidazol-1-yl-2-methyl-phenylamine 
• 468740-98-9 4-imidazol-1-yl-2-methyl-6-nitro-phenylamine 
• 928261-59-0 2,2,2-trifluoro-N-(4-imidazol-1-yl-2-methyl-6-nitro-phenyl)-acetamide 

Relevant articles and documents

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency.

Novel tyrosine kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

6-heteroaryl quinolone inotropic agents

A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared, including the 3,4-dihydro derivatives thereof, wherein the heterocyclic ring moiety is a pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the 5-, 6-, 7- or 8-positions of the quinolone ring. These particular compounds are useful in therapy as highly potent inotropic agents and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, 6-(2,4-dimethyl-5-nitroimadazol-1-yl)-8-methyl-2-(1H)-quinolone, 8-methyl-6-(tetrazol-1-yl)-2-(1H)-quinolone, 8-methyl-6-(1,2,4-triazol-4-yl)-2-(1H)-quinolone, and 6-(4-cyano-2-methylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, respectively. Methods for preparing these compounds from known starting materials are provided.